CRL (CRL) CEO Girshick delivers 618 shares for tax withholding, holds over 71K

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Chief Executive Officer Birgit Girshick reported routine share movements related mainly to taxes. On May 26 and 27, 2026, she had tax-withholding dispositions totaling 618 shares of common stock, with 376 shares at $160.30 and 242 shares at $156.73.

After these dispositions, she held 31,020 shares directly. A separate holding line shows an additional 40,417 common shares held indirectly through a revocable trust as of May 26, 2026. The filing reflects tax and ownership mechanics rather than open-market buying or selling.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Girshick Birgit

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	242	$156.73	$38K
Tax Withholding	Common Stock	376	$160.30	$60K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 31,020 shares (Direct, null); Common Stock — 40,417 shares (Indirect, Revocable Trust)

Footnotes (1)

Key Figures

Tax-withholding shares (May 27, 2026): 242 shares at $156.73 Tax-withholding shares (May 26, 2026): 376 shares at $160.30 Total tax-withholding shares: 618 shares +2 more

5 metrics

Tax-withholding shares (May 27, 2026) 242 shares at $156.73 Common stock delivered for tax liability, code F

Tax-withholding shares (May 26, 2026) 376 shares at $160.30 Common stock delivered for tax liability, code F

Total tax-withholding shares 618 shares Sum of F-code dispositions in this Form 4

Direct shares after transactions 31,020 shares CEO direct ownership following tax-withholding dispositions

Indirect shares in revocable trust 40,417 shares Indirect ownership through revocable trust as of May 26, 2026

Key Terms

tax-withholding disposition, Revocable Trust, Form 4

3 terms

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Revocable Trust financial

"nature_of_ownership": "Revocable Trust""

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girshick Birgit

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		F		376	D	$160.3	31,262	D
Common Stock	05/27/2026		F		242	D	$156.73	31,020	D
Common Stock								40,417	I	Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Birgit Girshick	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did CRL CEO Birgit Girshick report on this Form 4?

Birgit Girshick reported two tax-withholding dispositions of Charles River Laboratories common stock totaling 618 shares. These were payments of tax liabilities using shares, not open-market sales or purchases, and are typically part of routine equity compensation administration.

How many CRL shares were used for tax withholding by the CEO?

A total of 618 Charles River Laboratories common shares were used to satisfy tax obligations. The filing shows 376 shares at $160.30 per share and 242 shares at $156.73 per share, both classified as tax-withholding dispositions under transaction code F.

How many CRL shares does the CEO hold directly after these transactions?

Following the reported tax-withholding dispositions, Birgit Girshick directly holds 31,020 shares of Charles River Laboratories common stock. This figure reflects her remaining direct ownership stake after the 618 shares were delivered to cover tax liabilities related to equity compensation.

What indirect CRL holdings are reported for the CEO on this Form 4?

The Form 4 shows an indirect holding of 40,417 Charles River Laboratories common shares held through a revocable trust as of May 26, 2026. This entry is labeled as indirect ownership, separate from Girshick’s directly held 31,020 shares after the tax-related dispositions.

Were any open-market buys or sells of CRL stock reported by the CEO?

No open-market purchases or sales are reported in this Form 4. The only share movements are coded as F transactions, meaning shares were delivered to pay tax liabilities, plus one holding line for a revocable trust, so no traditional buy or sell orders appear.